Evidence map›Paper›PMID 40727281›Full record

ReviewRSC advances2025

Graphene-based nanomaterials: mechanisms and potentials in the fight against multidrug resistant bacterial infections: a review.

Jianling Huang, Dengke Zhang, Chenghua Zhu, Shijun Chen, Yueyue Wang, Kexing Han, Shusheng Ci, Yunxiang Lv

Abstract readReview
In one paragraph

Review in RSC advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Multifunctional rGO/YRSC advances · 2026
    Article
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Jianling HuangDepartment of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Bengbu Medical University Bengbu Anhui 233000 China yunxianglv@126.com.ORCID https://orcid.org/0000-0001-9000-4336
Dengke ZhangDepartment of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Bengbu Medical University Bengbu Anhui 233000 China yunxianglv@126.com.
Chenghua ZhuNanjing Pukou Hospital of TCM, Pukou Hospital of Chinese Medicine Affiliated to China Pharmaceutical University Nanjing 210000 China zhuchenghuacheng@163.com.
Shijun ChenDepartment of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Bengbu Medical University Bengbu Anhui 233000 China yunxianglv@126.com.
Yueyue WangDepartment of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Bengbu Medical University Bengbu Anhui 233000 China yunxianglv@126.com.
Kexing HanDepartment of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Bengbu Medical University Bengbu Anhui 233000 China yunxianglv@126.com.
Shusheng CiDepartment of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Bengbu Medical University Bengbu Anhui 233000 China yunxianglv@126.com.
Yunxiang LvDepartment of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Bengbu Medical University Bengbu Anhui 233000 China yunxianglv@126.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Bacterial infections pose a serious threat to human health, and antibiotic resistance has greatly hindered their clinical application. Therefore, new antibacterial compounds or alternative approaches are urgently needed. In recent years, nanoscience and nanotechnology have developed a number of antimicrobial nanoparticles that can be used as new tools to fight deadly bacterial infections. Graphene-based nanomaterials (GBNs), such as graphene oxide (GO) and reduced graphene oxide (rGO), have shown great potential in the treatment and management of bacteria-induced infectious diseases due to their outstanding biological properties. This review provides a comprehensive understanding of the antibacterial application of GBNs

Identifiers

PMID40727281
PMCPMC12301877

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.